论文部分内容阅读
目的观察CHOP+美罗华初治和复治B细胞非霍奇金淋巴瘤的疗效。方法6例患者均经病理组织学证实为CD20阳性的B细胞非霍奇金淋巴瘤。2例为初治者,4例为复发难治者,CHOP按标准方案,共6~8疗程。美罗华375mg/m2,静脉滴注,1次/周,共4周为1疗程。结果完全缓解4例,部分缓解1例,无效1例,有效率为83%。随访时间2~6年,除1例无效死亡,其余保持完全缓解或部分缓解。结论美罗华对CD20阳性的B细胞非霍奇金淋巴瘤疗效肯定,尤其在清除微小残余病灶、减少复发方面疗效显著。
Objective To observe the curative effect of CHOP + rituximab treatment and retreatment B cell non-Hodgkin’s lymphoma. Methods Six patients were confirmed by histopathology as CD20 positive B cell non-Hodgkin’s lymphoma. 2 cases of naive, 4 cases of relapsed and refractory, CHOP according to the standard program, a total of 6 to 8 courses. Rituximab 375mg / m2, intravenous infusion, 1 / week, a total of 4 weeks for a course of treatment. Results of complete remission in 4 cases, partial remission in 1 case, ineffective in 1 case, the effective rate was 83%. Follow-up time of 2 to 6 years, except one case died, the remaining remained completely relieved or partially relieved. Conclusion Rituximab has a positive curative effect on CD20 positive B-cell non-Hodgkin’s lymphoma, especially in the treatment of minimal residual lesions and reduction of recurrence.